Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
Exhibit 99.1
POMDOCTOR LIMITED Highlights Differentiated
“Hardware + AI + Payment” Healthcare Infrastructure Model
GUANGZHOU, China, September 24, 2026 /PRNewswire/
-- POMDOCTOR LIMITED (“Pomdoctor” or the “Company”) (NASDAQ: POM), a digital healthcare company focused on
advancing AI-enabled healthcare solutions, today highlighted its differentiated “hardware + AI + payment” infrastructure model.
The Company believes this integrated approach distinguishes it from traditional internet healthcare platforms and positions Pomdoctor
to evolve into a comprehensive digital healthcare technology infrastructure provider.
While conventional internet healthcare platforms
typically operate in silos, focusing on discrete services such as online consultations, prescription processing or pharmaceutical transactions,
Pomdoctor aims to develop a full-cycle predictive healthcare infrastructure. This system is designed to integrate continuous health monitoring,
AI-powered analysis, physician intervention, healthcare payment and fulfillment within a unified, closed-loop ecosystem.
From a global industry perspective, Pomdoctor’s
model seeks to consolidate capabilities that are typically fragmented across different digital health categories. Wearable technology
companies such as Oura demonstrate the value of continuous, longitudinal health-data capture; virtual healthcare platforms such as Teladoc
Health validate the effectiveness of digitally delivered medical consultations; and AI healthcare technology companies such as Tempus
AI prove the potential of applying AI analytics to real-world data for actionable insights.
Pomdoctor’s strategy is to converge these
capabilities into one integrated healthcare ecosystem, moving beyond standalone solutions to create a synergistic infrastructure where
the combined value of connected data, AI, clinical services, and payment capabilities can exceed that of individual components operating
independently.
The Company believes this integrated model offers
three distinct core advantages:
| ● | Healthcare and Compliance Foundation. Pomdoctor
has established robust physician networks, proprietary clinical workflows, rigorous prescription protocols and a mature pharmaceutical
fulfillment infrastructure in China. This operational foundation is built around compliant, real-world medical delivery, providing a high
barrier to entry for pure-play tech competitors. |
| ● | Proprietary Wearable Device Gateway. The
Company is developing a portfolio of proprietary wearable technologies designed to function as a continuous healthcare data gateway. By
collecting longitudinal physiological and behavioral data, these devices generate a high-frequency, real-world data stream that can support
Pomdoctor’s predictive AI models, enabling earlier risk detection and proactive health management. |
| ● | Native Integration with Healthcare Payment
Networks. A key differentiator of Pomdoctor’s model is its deep integration with China’s healthcare payment systems. By
embedding payment capabilities directly into its ecosystem, including connectivity with commercial insurers and local medical savings
accounts-based health management, the Company seeks to close the healthcare delivery loop. This integration is designed not only to facilitate
patient access and adherence, but also to create a scalable and monetizable pathway for the Company’s services. |
By combining these capabilities, Pomdoctor believes
its long-term value proposition warrants evaluation beyond the traditional metrics applied to standalone telemedicine or internet healthcare
platforms. The Company believes that its future performance should increasingly be assessed through a digital healthcare technology
infrastructure lens -- one that considers the compounding value of proprietary hardware, AI-driven data assets, clinical services,
and payment connectivity. This comprehensive framework, the Company asserts, can offer analysts and investors a broader perspective on
its evolving business model and sustainable growth trajectory.
Mr. Zhenyang Shi, Chairman and Chief Executive
Officer of Pomdoctor, commented, “We believe the future of digital healthcare lies not in a single product or service, but in the
integration of data, technology, medical services and payment infrastructure. By connecting wearable devices, AI intelligence, physician
resources and healthcare payment capabilities, we are constructing an integrated infrastructure that supports continuous and predictive
healthcare across the full patient journey.”
About POMDOCTOR LIMITED
POMDOCTOR LIMITED (NASDAQ: POM) is a digital
healthcare company focused on advancing AI-enabled healthcare solutions and expanding predictive healthcare capabilities. The Company
leverages physician resources, wearable technologies, artificial intelligence, healthcare payment networks and real-world healthcare data
to support more personalized, continuous and data-driven healthcare services. Building upon its established healthcare platform and physician
network, POM is pursuing the development of a predictive healthcare data and services infrastructure designed to improve healthcare outcomes
and create long-term value for patients, healthcare providers and other ecosystem participants. For more information, please visit the
Company’s website: http://ir.7shiliu.com.
Forward-Looking Statements
Certain statements in this announcement are forward-looking
statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current
expectations and projections about future events that the Company believes may affect its financial condition, results of operations,
business strategy and financial needs. Investors can find many (but not all) of these statements by the use of words such as “approximates,”
“believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,”
“intends,” “plans,” “will,” “would,” “should,” “could,” “may”
or other similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect
subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes
that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn
out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages
investors to review other factors that may affect its future results in the Company’s filings with the SEC.
For more information, please contact:
POMDOCTOR LIMITED
Investor Relations Department
Email: ir@7lk.com
Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email: investors@ascent-ir.com
